Pre-IPO Raily Aesthetic Medicine (2135.HK) - Here Are the Concerns
577 Views24 Dec 2020 09:41
The article analyzed the major concerns of Raily Aesthetic Medicine in terms of financial position, high-quality talents, domestic regulations and other business risks.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Policy Update - The Official Results of 2020 Medical Insurance Negotiations04 Jan 2021
- Industry Report - Insights on China Medical Beauty Industry29 Dec 2020
- China Healthcare Weekly (Dec.25)28 Dec 2020
- Pre-IPO Raily Aesthetic Medicine (2135.HK) - Here Are the Concerns24 Dec 2020
- Pre-IPO Basecare Medical - Here Are the the Strengths and Concerns23 Dec 2020
- Pre-IPO MicroPort CardioFlow - A Better Candidate of the TAVR Market in China?16 Dec 2020
- JD Health (6618.HK) - Opportunities Coexist with Challenges15 Dec 2020
x